ライフサイエンスコーパス: local recurrence

1 29 months, 6 patients (3%) have experienced local recurrence.

2 term tumor surveillance, perhaps more so for local recurrence.

3 f 982 patients, 35 patients (3.6%) developed local recurrence.

4 May 1998 and December 2008 were reviewed for local recurrence.

5 tic potential but with a significant risk of local recurrence.

6 ain by hypothetical top-down modification of local recurrence.

7 97.6%); 2 patients underwent enucleation for local recurrence.

8 es only if V1 operates in a regime of strong local recurrence.

9 ho did not undergo a second operation showed local recurrence.

10 year DSS was 86% and 1 patient experienced a local recurrence.

11 c leak predisposes rectal cancer patients to local recurrence.

12 otic leakage was not associated with risk of local recurrence.

13 uggest young age is a predictor of increased local recurrence.

14 e survival and inversely with tumor size and local recurrence.

15 ed of metastatic disease with no evidence of local recurrence.

16 The primary outcome measure was local recurrence.

17 pendently influenced development of a second local recurrence.

18 ainty for the management of surveillance for local recurrence.

19 hieved is an important prognostic factor for local recurrence.

20 d survival after aggressive resection of the local recurrence.

21 underwent complete resection of their first local recurrence.

22 cervical carcinoma and evaluate the risk of local recurrence.

23 patients undergo additional surgery to avoid local recurrence.

24 The primary endpoint was local recurrence.

25 T after BCS on the basis of risk factors for local recurrence.

26 ermic intraperitoneal chemotherapy will have local recurrence.

27 to stratify patients on the basis of risk of local recurrence.

28 ion seems to be an important risk factor for local recurrence.

29 ed no statistical differences in outcomes of local recurrence (14% vs. 15%), enucleation (14% vs. 11%

30 /250); from these, 65.2% (45 patients) had a local recurrence, 18.8% (13 patients) a single lymph nod

31 e (1) what constitutes an acceptable risk of local recurrence, (2) what are the costs associated with

32 99 patients had developed local recurrence (27 preoperative radiotherapy vs 72 sel

33 Among 61 patients with local recurrence, 32 patients (52.4%) were correctly dia

34 in 27% of patients who experienced isolated local recurrence, 33% of patients with a distant recurre

35 CPNI compared with those with CSCC and IPNI (local recurrence, 37% vs 17%; P < .001; disease-specific

36 erential resection margin, mesorectal grade, local recurrence (4% vs 5%, P = 0.98), and disease-free

37 Local recurrence (5-year, 51% vs. 54%, P = 0.11) and ove

38 low-up of 47 months, there were a total of 7 local recurrences (5%): 1, 0, and 6 in the stapled anast

39 nd prosthesis fracture (1 patient, 0.6%) and local recurrence (6 patients, 3.9%).

40 with no response, experienced lower rates of local recurrence (6% v.

41 n CAP45 and CAPOX50 (cumulative incidence of local recurrence, 6.1% v 4.4%; overall survival, 87.6% v

42 Seventeen eyes (85%) showed no local recurrence after a median follow-up of 65 months (

43 iting policy with intervention when invasive local recurrence after breast-conserving surgery is dete

44 s that determine survival in patients with a local recurrence after complete resection of the primary

45 did not expose patients to complications or local recurrence after enucleation.

46 umferential resection margin on survival and local recurrence after esophagectomy are conflicting.

47 Increased local recurrence after excision of the primary tumors wa

48 histology predicts the 3- and 5-year risk of local recurrence after limb-sparing surgery in the absen

49 lvage radiotherapy with patients with PSA or local recurrence after prostatectomy.

50 AL has a negative prognostic impact on local recurrence after restorative resection of rectal c

51 eyond the margins of the main tumor mass and local recurrence after surgery.

52 Treatment failure included local recurrence alone in 75 patients (14%) and systemic

53 /161 [3.1%]) with iris melanoma demonstrated local recurrence and 1 metastasized.

54 section margin is the primary determinant of local recurrence and a major factor in survival in recta

55 including only size, site, and age predicts local recurrence and can aid in counseling patients.

56 resectable MRD, PNB-guided surgery prevented local recurrence and delivered 100% tumour-free survival

57 TAE) itself--were independent predictors of local recurrence and DFS.

58 th CSCC and CPNI are at an increased risk of local recurrence and disease-specific death compared wit

59 The overall risks of local recurrence and disease-specific death were signifi

60 Five-year crude cumulative incidences of local recurrence and distant metastasis for radical vers

61 moresistance is considered the main cause of local recurrence and distant metastasis in lung cancer.

62 ative breast cancer (TNBC) has high rates of local recurrence and distant metastasis, partially due t

63 drug resistance) are likely to give rise to local recurrence and distant metastatic relapse.

64 sion alone is associated with a high risk of local recurrence and inferior survival compared with tra

65 Suspicion of local recurrence and inflammation required a biopsy conf

66 Local recurrence and inflammation were confirmed by a bi

67 r depth is associated with the highest RR of local recurrence and metastasis of cSCC, and tumor diame

68 have a poor prognosis owing to high rates of local recurrence and metastasis to distant organs.

69 t create a regenerative environment favoring local recurrence and metastasis.

70 unctival surface melanomas is complicated by local recurrence and metastatic disease, particularly fo

71 onventional therapy and are the "drivers" of local recurrence and metastatic spread.

72 Local recurrence and overall 5-year survival rates were

73 r positive or negative) for the diagnosis of local recurrence and pelvic LN and bone metastases was m

74 Documented local recurrence and pelvic LN and bone metastases was p

75 R imaging versus PET/CT for the diagnosis of local recurrence and pelvic LN and bone metastases were

76 ion margin is associated with a high rate of local recurrence and poor morbidity and mortality for re

77 nd suggest that serum LIF levels may predict local recurrence and radiosensitivity in NPC patients.

78 sess clinical and surgical factors affecting local recurrence and survival in young breast cancer pat

79 We report 5-year results for local recurrence and the first analysis of overall survi

80 ncer is accepted as the best means to reduce local recurrence and thereby improve survival, there is

81 ), four out of 27 patients (14.8%) developed local recurrence and underwent salvage total laryngectom

82 mary site, we found a low occurrence of true local recurrences and satellite recurrences.

83 rgery alone, patients may remain at risk for local recurrences and/or metastatic disease.

84 monstrated metastases, there were 2 cases of local recurrence, and 16% (n = 21) underwent enucleation

85 etastatic spread to the surgical bed causing local recurrence, and another case of cross-metastatic s

86 hat are the benefits of endocrine therapy on local recurrence, and do they justify the additional tox

87 pe and is associated with indolent behavior, local recurrence, and insensitivity to radiotherapy and

88 idity, mortality, complications, radicality, local recurrence, and metastasis.

89 er T stage was significantly associated with local recurrence, and recurrent tumors had a 4-fold incr

90 included perioperative morbidity, mortality, local recurrence, and survival.

91 survival, cancer-specific 5-year mortality, local recurrence, and the development of metastatic dise

92 ctival melanoma reveals a nearly 50% rate of local recurrence, and up to a 38% 10-year mortality.

93 me show malignant morphological features and local recurrences are not uncommon; a few may even metas

94 Since metastasis is rarely seen and local recurrences are uncommon following wide excision w

95 t lesions in 64 of 107 patients (59.8%), and local recurrence as well as distant lesions in 25 of 107

96 Local recurrence at 3 years was collected from the regis

97 local control in older women at low risk of local recurrence at 5 years.

98 ed by biopsy for all patients in the case of local recurrence before surgery.

99 dal involvement was significantly related to local recurrence but more strongly related to distant me

100 esection, whole brain radiotherapy decreases local recurrence, but might cause cognitive decline.

101 argins are associated with increased risk of local recurrence, but there is no consensus regarding op

102 s (52.4%) were correctly diagnosed as having local recurrence by both multiparametric MR imaging and

103 RT was associated with significantly reduced local recurrence compared with conventional EBRT for pri

104 SRS) to the surgical cavity improved time to local recurrence compared with that for surgical resecti

105 three brain metastases significantly lowers local recurrence compared with that noted for observatio

106 what are the costs associated with managing local recurrences compared with RT given initially after

107 Local recurrence developed in 3 patients; 1 of them unde

108 OBJECTIVE:: To assess local recurrence, disease-free survival, and overall sur

109 was no association between clinical leak and local recurrence, disease-free survival, or overall surv

110 linical leak was not associated with time to local recurrence, disease-free survival, or overall surv

111 re correlated to the cumulative incidence of local recurrence, distant metastasis, and disease-free s

112 Outcomes evaluated included local recurrence, distant recurrence, and cancer specifi

113 Outcomes evaluated were local recurrence, distant recurrence, and survival.

114 this information along with outcome data for local recurrence, distant recurrence, disease specific,

115 ion therapy is effective against this tumor, local recurrence due to radioresistance is an important

116 Two patients had a local recurrence during the follow-up period, one of who

117 is the reason for a relatively high rate of local recurrence, even after surgical removal.

118 ntly demonstrated a reduction in the risk of local recurrence following breast-conserving surgery (BC

119 This case highlights a local recurrence following use of this new treatment mod

120 Local recurrences following brachytherapy are uncommon 5

121 reoperative radiotherapy reduced the rate of local recurrence for all three plane of surgery groups,

122 d a reduction of 61% in the relative risk of local recurrence for patients receiving preoperative rad

123 ted in a significant but modest reduction in local recurrence for women aged 65 years or older with e

124 tastases; in the SABR group, one patient had local recurrence, four had regional nodal recurrence, an

125 ess associations with the primary endpoints: local recurrence-free survival (LRFS) and disease-specif

126 were 3-year disease-free survival (DFS) and local recurrence-free survival (LRFS).

127 s no statistically significant difference in local recurrence-free survival (P = 0.13).

128 Study endpoints included second local recurrence-free survival for these 61 patients and

129 Before RFA, factors predicting greater local recurrence-free survival included initial lesion s

130 nal wall tumors had the best outcome (5-year local recurrence-free survival rate of 91%).

131 Five-year local recurrence-free survival was 69%.

132 Three-year estimated local recurrence-free survival was 89.2% (95% CI, 0.748

133 Three-year local recurrence-free survival was 96.9%, metastasis-fre

134 Efficacy end points were local recurrence-free survival, metastasis-free survival

135 t radiation was not associated with improved local recurrence-free survival.

136 meter significantly associated with overall, local recurrence-free, disease-free, and distant metasta

137 the efficacy and utility of RFA to increase local recurrence-free, progression-free, and disease-fre

138 ) and 82% (95% CI, 79-84), and those for the local recurrence group were 71% (95% CI, 62-78) and 62%

139 ressive operative management patients with a local recurrence growth rate greater than 0.9 cm/mo were

140 going reresection, local recurrence size and local recurrence growth rate independently influenced de

141 Local recurrence growth rate is strongly associated with

142 e, primary histologic variant and grade, and local recurrence growth rate were independent predictors

143 Only patients with local recurrence growth rates of less than 0.9 cm/mo wer

144 nd rerecurrence after resection of the first local recurrence have not been clearly defined.

145 sion, there was a 9% increase in the rate of local recurrence (hazard ratio, 1.09; 95% CI, 1.02-1.15;

146 ated by conventional imaging and identifying local recurrence hidden by treatment changes on conventi

147 Local recurrence HR for MRI-involved CRM was 3.50 (95% C

148 5%CI, 0.30-0.93), and less likely to develop local recurrence (HR = 0.54; 95%CI, 0.29-0.99).

149 thout adjuvant treatment was associated with local recurrence (HR, 1.97; 95% CI, 0.11-3.48; P = .02),

150 rascleral extension also was associated with local recurrence (HR, 3.2; 95% CI, 1.5-6.7; P = 0.003),

151 tumor diameter of 2 cm or greater predicted local recurrence (HR, 4.8 [95% CI, 1.8-12.7]), >1 risk f

152 odal metastases were found in 5 (18%) of 28, local recurrence in 2 (7%) of 28, cervical nodal and dis

153 14%) and systemic metastases with or without local recurrence in 226 patients (42%).

154 (68)Ga-PSMA ligand PET/CT indicated local recurrence in 68 of 107 patients (63.5%), distant

155 eablation and postablation scans may predict local recurrence in patients treated with RFA for lung m

156 s to be associated with an increased risk of local recurrence in patients with C-MIN with atypia and

157 stoperative radiotherapy reduces the risk of local recurrence in patients with operable rectal cancer

158 e plane of surgery groups, almost abolishing local recurrence in short-course preoperative radiothera

159 specific considerations for the detection of local recurrence in the case of rectal cancer, as well a

160 The Kaplan-Meier estimate of local recurrence in the conserved breast at 4 years was

161 The 5-year risk for local recurrence in the conserved breast was 3.3% (95% C

162 e primary outcome was absolute difference in local recurrence in the conserved breast, with a prespec

163 The primary outcome was local recurrence in the conserved breast.

164 is original surgery, the patient developed a local recurrence in the foot, and over the subsequent 6

165 The reviewers assessed for local recurrence in the prostatectomy bed as well as LN

166 The primary endpoint was time to local recurrence in the resection cavity, assessed by bl

167 High rates of local recurrence in tobacco-related head and neck squamo

168 At 4 years, there were six local recurrences in the intraoperative radiotherapy gro

169 s (range, 92-257 days) after ablation showed local recurrences in two (7%) lesions that were original

170 l globe-retaining retreatment approaches for local recurrence, including proton beam therapy, brachyt

171 Endpoints were local-recurrence interval (LRI), distant disease-free in

172 The mechanism through which SEAL increases local recurrence is an important area for future researc

173 are associated with higher event rates, and local recurrence is associated with reduced overall surv

174 the primary site in patients at low risk for local recurrence is questionable.

175 (OS) and crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM) were c

176 study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in yo

177 the association between preoperative MRI and local recurrence (LR) as primary outcome, as well as dis

178 herapy (BCT) have shown substantial rates of local recurrence (LR) in young patients with breast canc

179 survival (RFS), distant metastasis (DM), and local recurrence (LR) rates were compared among patients

180 SBRT reduced the risk of local recurrence (LR), 4% versus 20% for wedge (P = .07)

181 sociation with disease-specific death (DSD), local recurrence (LR), and distant recurrence (DR).

182 r non-small-cell lung cancer (NSCLC) is high local recurrence (LR).

183 S), disease-free survival (DFS), and time to local recurrence (LR).

184 The primary outcome measure was local recurrence (LR).

185 CIS) aims at reduction of the incidence of a local recurrence (LR).

186 reast tumors are predictive of breast cancer local recurrence (LR).

187 Women's Hospital tumor stage) and outcomes (local recurrence [LR], nodal metastases [NM], and death

188 Poor outcomes (local recurrence [LR], nodal metastasis [NM], and diseas

189 IN with atypia and with an increased risk of local recurrence, lymphatic spread, distant metastasis,

190 When considering rates of local recurrence, metastases, and late radiation adverse

191 Subhazard ratios for local recurrence, nodal metastasis, disease-specific dea

192 ies that reported a disease-related outcome (local recurrence, nodal metastasis, distant metastasis,

193 he development of poor skin cancer outcomes (local recurrence, nodal metastasis, distant metastasis,

194 After breast-conserving surgery, 90% of local recurrences occur within the index quadrant despit

195 True local recurrence occurred in 1 patient with concurrent i

196 Local recurrence occurred in 17 treated patients (6.8%).

197 Local recurrence occurred in 45 patients (4.6%) during t

198 Only a single local recurrence occurred in cases with no risk factors

199 None of the two true local recurrences occurred at the site of the vessel.

200 We report a case of local recurrence of basal cell carcinoma (BCC) and ocula

201 END/DeltaEND) mice had significantly greater local recurrence of cancer following resection, elevated

202 An IBE was defined as local recurrence of DCIS or invasive carcinoma in the tr

203 by salvage rectal resection with no further local recurrence of disease (median follow-up 17 months)

204 (IJV) after subtotal thyroidectomy caused by local recurrence of papillary thyroid carcinoma is extre

205 asonographically guided biopsy for suspected local recurrence of prostate cancer after definitive ext

206 alternative to enucleation in patients with local recurrence of PUM, yielding high rates of local co

207 Local recurrence of rectal cancer is more common after a

208 vehicle, gemcitabine significantly inhibited local recurrence of tumors, but not metastasis to distan

209 ll-mediated antitumor responses and inhibits local recurrence of tumors, consistent with observations

210 We evaluated 48 patients with local recurrence of uveal melanoma after primary treatme

211 In breast cancer (BC) patients, local recurrences often arise in proximity of the surgic

212 Nineteen patients (19%) had local recurrence only.

213 ves, more patients are at risk of developing local recurrence or a new primary tumour in previously i

214 rocedures in patients presenting with either local recurrence or de-novo lesions in the ipsilateral k

215 There have been no cases of local recurrence or metastatic progression at median 21.

216 r glaucoma (NVG) and enucleation (mainly for local recurrence or NVG) were 27.0% and 19.5%, respectiv

217 some advantage with regard to delineation of local recurrence or pelvic lymph node metastasis in sele

218 A local recurrence or remnant tumor was found in two patie

219 carried out in 14 patients (9.5%) because of local recurrence or severe side effects.

220 e of endophthalmitis, orbital dissemination, local recurrence, or rhegmatogenous retinal detachment.

221 Estimated local recurrence, overall survival, and disease-specific

222 tly associated with both PNI (P = 0.035) and local recurrence (P < 0.001).

223 le statistically significant risk factor for local recurrence (P = .00001).

224 67), significantly improved the detection of local recurrence (P = .001).

225 tients and one of 31 LC patients experienced local recurrence (P = .21).

226 or the outcomes of use of TME (P < 0.01) and local recurrence (P = 0.01).

227 no statistically significant differences in local recurrence (P = 0.11) or regional recurrence (P =

228 urvival (P = 0.317 and 0.655, respectively), local recurrence (P = 0.716 and 0.900, respectively), or

229 val, thereby observing tumor stage-dependent local recurrence, peritoneal carcinomatosis, and lung me

230 rectal coil is superior for the detection of local recurrence, PET/CT is superior for pelvic LN metas

231 ositive surgical margins, and development of local recurrence predicted for reduced DDFI (HR = 0.50,

232 In case of early detection of local recurrence, preservation of the globe can be warra

233 For local recurrence, pretreatment imaging features were not

234 This relatively low rate of local recurrence questions the need for adjuvant RT to t

235 results in a significantly increased 3-year local recurrence rate as compared with standard APE.

236 t 79.5% for ESD vs. 59% for EMR, and a lower local recurrence rate at 0.82% for ESD vs. 5.03% for EMR

237 nal verge), no significant difference in the local recurrence rate could be observed.

238 on is associated with a worse prognosis, but local recurrence rate does not differ significantly from

239 The local recurrence rate for this series of patients predic

240 followed up for a minimum of 3 years, with a local recurrence rate of 2.4%, and a distant recurrence

241 The 4-year local recurrence rate was 0% (95% CI, 0% to 11%); the 4-

242 The local recurrence rate was 10%, the regional nodal recurr

243 a follow-up of 51 months (range, 1-151), the local recurrence rate was 4% and overall survival and di

244 The local recurrence rate was 6.0% overall and was highest f

245 Five-year estimated local recurrence rate was 6.6%.

246 The STS nomogram predicted the local recurrence rate with a C-index of 0.73.

247 included transplant type, number of cancers, local recurrence rate, lymph node involvement, lymphatic

248 To investigate the local recurrence rates and margin to clearance end point

249 Local recurrence rates and margin to clearance end point

250 The local recurrence rates at 3 years [median follow-up, 3.4

251 h neoadjuvant chemoradiotherapy achieves low local recurrence rates in clinical stages II to III rect

252 Local recurrence rates in operable rectal cancer are imp

253 .32 (95% CI 0.16-0.63, p=0.0011) with 3-year local recurrence rates of 6% (5-8%) and 17% (10-26%) for

254 for prognostic significance with respect to local recurrence rates using Gray's test.

255 The estimated local recurrence rates were 1.4% at 5 years, 1.8% at 7.5

256 tients), the overall 3- and 5-year actuarial local recurrence rates were 11% and 13%, respectively.

257 At 3 years, the estimated local recurrence rates were 4% (3-6%) for mesorectal, 7%

258 val based on the surgical approach; however, local recurrence rates were highest for percutaneously a

259 Local recurrence rates were similar: 12% versus 13% (P=0

260 abdominoperineal excision (ELAPE) regarding local recurrence rates within 3 years after surgery.

261 n addition to significantly increased 3-year local recurrence rates, the significantly increased inci

262 Despite higher local-recurrence rates for BCS, surgical type does not i

263 BRAF mutations, local recurrence, regional and distant metastasis, melan

264 as also associated with an increased risk of local recurrence (relative risk, 3.62).

265 , tumor size, vascularity and prognosis, and local recurrence seeded by disseminated cells following

266 ned with BS in diagnosing distant, bone, and local recurrence, shown by a greater area under the rece

267 For those undergoing reresection, local recurrence size and local recurrence growth rate i

268 Local recurrence size, primary histologic variant and gr

269 advances in the management of rectal cancer, local recurrence still occurs.

270 erential resection margin, mesorectal grade, local recurrence, survival, and functional outcome.

271 Depending on the value placed on local recurrence, Tam remains a reasonable option for wo

272 therapeutic challenge with a higher risk of local recurrence than other types of melanoma correctly

273 nts receiving whole-breast irradiation had a local recurrence; the cumulative incidence of local recu

274 e follow-up for patients with a high risk of local recurrence to assess for recurrence.

275 or overall survival, distant metastases, and local recurrence using only clinical factors, clinical f

276 ocal recurrence; the cumulative incidence of local recurrence was 1.44% (95% CI 0.51-2.38) with APBI

277 months (14-365 months), while median time to local recurrence was 43 months (9-185 months).

278 The median time to local recurrence was 43 months, the median time to dista

279 12-month freedom from local recurrence was 43% (95% CI 31-59) in the observati

280 Local recurrence was correlated with a higher risk for m

281 Local recurrence was detected up to 9.8 years after trea

282 When local recurrence was included in the model as a time-dep

283 RFA) and for the detection and prediction of local recurrence was investigated.

284 Local recurrence was observed in 0% to 7% of the patient

285 A step-wise increase in local recurrence was observed in WT, neu-tolerant, and S

286 < .001 and P = .039, respectively), whereas local recurrence was significantly affected by ypN statu

287 Local recurrence was similar between groups.

288 of multiparametric MR imaging for diagnosing local recurrence were 88.5% (54/61), 84.6% (22/26), and

289 -Meier point estimates for remaining free of local recurrence were 99% (95% CI, 99-99) at 1 year, 93%

290 older age, T2 disease, high tumor grade, and local recurrence were associated with reduced overall su

291 Overall survival, disease-free survival, and local recurrence were calculated.

292 atients with small lymph node metastases and local recurrence were not excluded from treatment, consi

293 Higher rates of local recurrence were noted in HCC patients, which may r

294 Importantly, local recurrences were eliminated or greatly reduced in

295 tomoses, the odd ratios (OR) of developing a local recurrence when there was AL was 2.05 (95% CI = 1.

296 both colon and rectal anastomoses, the OR of local recurrence when there was an AL was 2.9 (95% CI =

297 common cancers, but many patients experience local recurrence with metastatic disease.

298 maining 8589 patients, 861 (10.0%) developed local recurrence with no association to AL [adjusted haz

299 Most patients (n = 22) had local recurrence, with 82% (18 of 22) having unifocal di

300 atients (4.7%) with CBC melanoma experienced local recurrence, with a cumulative incidence of 11%.